膀胱内A型肉毒毒素注射后尿路感染定义不一致的系统综述
该系统综述检索MEDLINE和Embase,纳入50项关于成人特发性膀胱过度活动症和/或神经源性逼尿肌过度活动患者接受膀胱镜下onabotulinumtoxinA注射且报告尿路感染结局的原始研究。仅54%的研究定义了尿路感染的诊断标准,共出现10种定义,且无一项膀胱过度活动症研究采用符合EAU标准的定义,提示尿路感染定义异质且常缺失。
要点
- 仅54%的研究定义了尿路感染诊断标准,共10种定义。
- 无膀胱过度活动症研究采用符合EAU标准的尿路感染定义。
- 神经源性膀胱研究中仅2/10采用符合NIDRR标准的定义。
核心结论
- 关于onabotulinumtoxinA治疗膀胱过度活动症和/或神经源性膀胱的文献中,尿路感染定义异质且经常缺失。
- 鉴于术后可能出现泌尿系统症状,明确标准对确定真实尿路感染率至关重要。
研究设计与样本
- 系统综述,检索MEDLINE和Embase,纳入50项原始研究。
- 研究对象为接受膀胱镜下onabotulinumtoxinA注射的成人特发性膀胱过度活动症和/或神经源性逼尿肌过度活动患者,且尿路感染为报告结局。
主要发现
- 共识别299篇文献,50篇符合纳入标准。
- 27项研究(54%)定义了尿路感染诊断标准,共包含10种定义。
- 无膀胱过度活动症研究采用符合EAU标准的尿路感染定义。
- 10项神经源性膀胱研究中仅2项采用符合NIDRR标准的尿路感染定义。
关键数值与推荐
- 27项研究(54%)定义了尿路感染诊断标准,共10种定义。
- 无膀胱过度活动症研究采用符合EAU标准的尿路感染定义。
- 10项神经源性膀胱研究中仅2项采用符合NIDRR标准的尿路感染定义。
临床怎么用
- 临床解读onabotulinumtoxinA注射后尿路感染率时需注意定义异质性。
- 建议在临床实践和研究中采用明确的尿路感染诊断标准以准确评估感染率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To more accurately examine the rate of urinary tract infection following onabotulinumtoxinA injection of the bladder we systematically reviewed the literature for definitions of urinary tract infection in studies of onabotulinumtoxinA injections. We assessed the studies for consistency with guideline statements defining urinary tract infections. MATERIALS AND METHODS: We systematically reviewed the literature by querying MEDLINE® and Embase®. We included original studies on adult patients with idiopathic overactive bladder and/or neurogenic detrusor overactivity who underwent cystoscopy with onabotulinumtoxinA injection and in whom urinary tract infection was a reported outcome. RESULTS: We identified 299 publications, of which 50 met study inclusion criteria. In 27 studies (54%) urinary tract infection diagnostic criteria were defined with a total of 10 definitions among these studies. None of the overactive bladder studies used a definition which met the EAU (European Association of Urology) criteria for urinary tract infection. Only 2 of the 10 studies on patients with neurogenic bladder used a urinary tract infection definition consistent with the NIDRR (National Institute on Disability and Rehabilitation Research) standards. CONCLUSIONS: Definitions of urinary tract infection are heterogeneous and frequently absent in the literature on onabotulinumtoxinA to treat overactive bladder and/or neurogenic bladder. Given the potential for post-procedure urinary symptoms in this setting, explicit criteria are imperative to establish the true urinary tract infection rate following treatment with onabotulinumtoxinA.
引用
- Stamm AW, Adelstein SA, Chen A, et al. Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review. J Urol. 2018. PMID: 29653162. doi:10.1016/j.juro.2018.03.132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。